US lawmakers blast patent thickets in letter to USPTO director
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

US lawmakers blast patent thickets in letter to USPTO director

retro banner with red vintage typewriter with a blank sheet of p

Three Republican and two Democratic Congress members have claimed that patent thickets hinder access to affordable medicine

Members from both sides of the US House of Representatives wrote to USPTO director Kathi Vidal on Friday, March 24, expressing their concern about “patent thicketing.”

Five members – three Republicans and two Democrats – urged Vidal to consider implementing the proposed policies outlined in her October 4 2022 request for comment.

Vidal’s suggested that parties seeking to overcome rejections based on obvious variations of prior claims should stipulate that those claims aren’t patentably distinct.

Such admission would ensure that if one of the duplicates was invalidated, courts could consider that fact as evidence against the others, the members claimed.

“Branded manufacturers will often seek numerous patents on a single feature of a drug, creating a dense web, or thicket, of patents that delay generic and biosimilar competition,” the letter said.

“While some may question the quality of these patents, the high cost, uncertainty, and lengthy process for challenging them, makes it practically impossible to sort the good from the bad.”

The letter added that patent thickets, the process of seeking multiple patents on a single feature of drug, protected older drugs from competition, which costs the US government and taxpayers more money and hinders patients’ options for cost-effective treatment.

The signees were Republican Jodey Arrington, Michael Burgess and Darrell Issa, and Democrats Lloyd Doggett and Annie Kuster.

Vidal’s October 2022 request for comment came about after President Joe Biden issued an executive order to promote access to drugs in 2021 and after six senators raised concerns about patent thickets in a June 2022 letter to the USPTO.

more from across site and ros bottom lb

More from across our site

Each week Managing IP speaks to a different IP practitioner about their life and career
Mathys & Squire has filed a test case that the firm hopes will make UPC pleadings available by default
Multiple representatives and their teams can now work on cases using the online CMS, but not everyone can submit documents
James Lawrence, partner at Addisons, explains how he convinced the full Federal Court of Australia to back his client in a patent dispute concerning mining safety equipment
The deal will allow the companies to use each other’s patents covering 4G and 5G technologies, and other cellular SEPs
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
Three lead IP counsel in the US, the UK and China share how they walk the fine line between building in-house competence and splurging on external lawyers
Mike Renaud, head of the IP division at Mintz, explains his business strategy and how the firm justifies charging higher rates
Sources say firms must build relationships with clients that transcend their connections to individual partners
INTA’s resolution on online marketplaces and appointment of Amazon’s general counsel follow calls for the association to take a direct position on internet fakes